Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
Allogene Therapeutics (ALLO) Stock Price & Analysis
1,064 Followers
ALLO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $6.89
Previous Close$3.5
Volume2.51M
Average Volume (3M)2.36M
Market Cap
$593.51M
Enterprise Value$239.93M
Total Cash (Recent Filing)$448.70M
Total Debt (Recent Filing)$88.35M
Price to Earnings (P/E)-1.7
Beta1.48
Next Earnings
May 01, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding169,091,992
10 Day Avg. Volume1,676,400
30 Day Avg. Volume2,361,780
Standard Deviation0.20
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.17
Price to Sales (P/S)6229.70
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.53K
Enterprise Value/Gross Profit2.53K
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$13.23Price Target Upside276.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Allogene Therapeutics News
PremiumCompany Announcements
Allogene Therapeutics’ Stability Threatened by Banking Sector Turmoil
Bulls Say, Bears Say
Bulls Say
Financial StabilityAllogene ended the year with roughly $448.7 million in cash and equivalents, providing an operational runway into 2026.
Pipeline PotentialAllogene's ALLO-329 product candidate in autoimmune diseases is unique, potentially eliminating the need for lymphodepletion and offering economies of scale.
Strategic DevelopmentALLO-501A's pivot into the first-line Large B-Cell Lymphoma setting is seen as a strategic move in an increasingly competitive field for CD19-targeted cell therapies.
Bears Say
Clinical TrialsLowering Rating to Market Perform due to discontinuation of late-stage trials.
Company OutlookWithout clarity on development timelines, valuation is based on estimated ending cash per share.
EarningsAllogene recorded a net loss of $0.51 per share—wider than the estimated net loss.
---
Ownership Overview
37.77% Insiders
30.04% Mutual Funds
14.64% Other Institutional Investors
17.56% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $2.23 and its highest was $6.89 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Currently, no data Available
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is May 01, 2024 which is in 13 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Mar 14, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.451 by -$0.059.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -$0.41.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 169,092,000 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.451. Following the earnings report the stock price went up 3.556%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 17M.
---
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.23 (276.92% Upside)
$13.23 (276.92% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $682.1 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q4 2024
0:00 / 0:00
---
ALLO Stock 12 Months Forecast
Average Price Target
$13.23
▲(276.92% Upside)
Technical Analysis
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-20.62%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -20.62% per trade.
---